Gene therapy is used for treating diseases caused due to genetic mutations, and it helps in repairing defects in an individual’s genes. Gene therapy helps in altering the genetic makeup and can be used for treating various genetic disorders. Cell therapy can be used to treat damaged cells by transplanting new cells and replacing the damaged cells. Plasmid DNA is used in various applications of gene therapy and also for clinical research.
The Journal of Gene Medicine, published their data in 2017, stating that there are around 2,600 gene therapy clinical trials that are either being carried on or completed or approved in 36 nations. China, the Netherlands, France, Australia, Switzerland and Japan are a few countries carrying out these clinical trials. Gene and cell therapies can be used for treating infectious diseases, cardiovascular diseases, inflammatory diseases and also cancer.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/4981
Rise in gene therapy approvals by the regulatory authorities for the treatment of individuals suffering from non-β0/β0 genotype and transfusion-dependent β-thalassemia is expected to boost the growth of the Middle East and Asia Pacific Cell and Gene Therapy Market during the forecast period. For instance, bluebird bio. Inc. received MAA (marketing authorization application) from the EMA (European Medicines Agency) in October 2018, for LentiGlobin gene therapy, used in the treatment of non-β0/β0 genotype and transfusion-dependent β-thalassemia in adults and adolescents.
Impact of COVID-19:
Many governments had imposed strict lockdowns worldwide due to the spread of COVID-19, this affected the economy negatively. Due to lockdown many industrial establishments were closed and supply chains of products were disturbed. The pandemic directly affected the production and demand in the market due to the disturbances caused in the distribution channels. The pandemic also affected financial markets and had an impact on many firms. Middle East and the Asia Pacific regions are facing many challenge regarding manufacturing and supply chain activities.
Moreover, there has been an increase in demand for equipment’s, manpower and consumables in the healthcare sector, in order to provide better care for patients. Supplying raw materials for manufacturing drugs has been a major challenge during COVID-19, as there have been disturbances in the transportation system. There has been an increase in demand for raw materials from product distributors for manufacturing products for gene therapy, as the number of people suffering from other life-threatening diseases is also increasing.
- Key players in the market are focusing on collaborations or partnerships which is anticipated to boost the growth of the Middle East and Asia Pacific Cell and Gene Therapy Market during the forecast period. For instance, SIRION Biotech, which develops viral vectors for cell and gene therapy declared partnership with a pharmaceutical company, Sanofi S.A. in February 2021 for enhancing adeno-associated virus capsids and for developing new gene therapy treatments.
- Furthermore, increase in the research and development activities for treating COVID-19 using stem cells is anticipated to propel growth of the cell therapy segment, among therapy type in the Middle East and Asia Pacific Cell and Gene Therapy Market. For instance, according to the United Arab Emirates Government portal, a group of researchers and doctors have successfully treated COVID-19 infection using stem cells at the Abu Dhabi Stem Cell Center-ADSCC in UAE.
Key players active in the Middle East and Asia Pacific cell and gene therapy market are Immuneel Therapeutics Pvt Ltd, Novartis International AG, Lonza, Pfizer Inc., WuxiAppTec, Sanofi S.A., uniQure N.V., Amgen Inc, JCR Pharmaceuticals Co. Ltd, Regeneron Pharmaceuticals Inc, Organogenesis, Inc, F. Hoffmann-La Roche AG, Biogen INC, Bluebird Bio Inc. (Celgene Corporation), Gilead Sciences Inc, Gene biotherapeutics, MeiraGTx Limited, Sibiono GeneTech Co. Ltd, Horama S.A and Kolon TissueGene, Inc.
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/4981
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Middle East and Asia Pacific Cell and Gene Therapy Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Middle East and Asia Pacific Cell and Gene Therapy Industry Impact
Chapter 2 Middle East and Asia Pacific Cell and Gene Therapy Competition by Types, Applications, and Top Regions and Countries
2.1 Middle East and Asia Pacific Cell and Gene Therapy (Volume and Value) by Type
2.3 Middle East and Asia Pacific Cell and Gene Therapy (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Middle East and Asia Pacific Cell and Gene Therapy Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 Company Profiles and Key Figures in Middle East and Asia Pacific Cell and Gene Therapy Business
Chapter 6 Middle East and Asia Pacific Cell and Gene Therapy Market Forecast (2022-2028)
Chapter 7 Conclusions
We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/4981
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, United States
Phone: US +12067016702 / UK +4402081334027